PROTAC HER2 degrader-1
Based on 1 Customer Validation
PROTAC HER2 degrader-1 is a selective HER2 PROTAC degrader with a DC50 of 69 nM. PROTAC HER2 degrader-1 induces ubiquitination and degradation of HER2 via the ubiquitin-proteasome system, thereby inhibiting the downstream PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling pathways. PROTAC HER2 degrader-1 inhibits the proliferation of HER2-positive cancer cells, induces apoptosis and arrests the cell cycle. PROTAC HER2 degrader-1 suppresses the growth of HER2-positive xenografts. PROTAC HER2 degrader-1 can be used in HER2-positive cancer-related research.
(Pink: HER2 ligand (HY-177009); Blue: Cereblon ligand (HY-W023573); Black: linker).
For research use only. We do not sell to patients.
- Purity : 98%
- CAS No.: 2897640-93-4
- Formula: C49H55N11O7
- Molecular Weight:910.03
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
HER2 69 nM (DC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BT-474 | IC50 |
0.047 nM
|
Antiproliferative activity against human HER2-positive BT-474 cancer cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
Antiproliferative activity against human HER2-positive BT-474 cancer cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
|
36208507 |
| SK-BR-3 | IC50 |
0.098 nM
|
Antiproliferative activity against human HER2-positive SK-BR-3 cancer cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
Antiproliferative activity against human HER2-positive SK-BR-3 cancer cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
|
36208507 |
| NCI-N87 | IC50 |
0.137 nM
|
Antiproliferative activity against human HER2-positive NCI-N87 cancer cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
Antiproliferative activity against human HER2-positive NCI-N87 cancer cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
|
36208507 |
| BT-474 | DC50 |
69 nM
|
Induction of HER2 protein degradation in human HER2-positive BT-474 cancer cells measured by Western blot assay.
Induction of HER2 protein degradation in human HER2-positive BT-474 cancer cells measured by Western blot assay.
|
36208507 |
| NCI-N87 | DC50 |
55 nM
|
Induction of HER2 protein degradation in human HER2-positive NCI-N87 cancer cells measured by Western blot assay.
Induction of HER2 protein degradation in human HER2-positive NCI-N87 cancer cells measured by Western blot assay.
|
36208507 |
In Vitro
PROTAC HER2 degrader-1 (CH7C4) potently and selectively inhibits the activity of purified HER2 kinase with an IC50 of 48.65 nM, while it exhibits much weaker inhibitory activity against EGFR kinase with an IC50 of 4383 nM. It potently suppresses the proliferation of HER2-positive BT-474, SK-BR-3 and NCI-N87 cancer cells, with IC50 values of 0.047 nM, 0.098 nM and 0.137 nM, respectively[1].
PROTAC HER2 degrader-1 (0.078-10 μM; 72 h) does not inhibit the proliferation of EGFR-driven A431 cells[1].
PROTAC HER2 degrader-1 (0.1-1000 nM; 1-24 h) efficiently induces concentration- and time-dependent HER2 degradation in BT-474 cells, with a DC50 of 69 nM and a Dmax of 96%; it also induces such degradation in NCI-N87 cells, with a DC50 of 55 nM and a Dmax of 94%[1].
PROTAC HER2 degrader-1 (10-1000 nM; 0-24 h) potently and persistently inhibits the PI3K/AKT and RAS/RAF/ERK signaling pathways downstream of HER2 in BT-474 and NCI-N87 cells by inducing HER2 degradation[1].
PROTAC HER2 degrader-1 (200 nM; 24 h) induces HER2 degradation in BT-474 cells via a ubiquitin-proteasome system-dependent mechanism. This process is blocked by UPS inhibitors, CRBN ligands and HER2 inhibitors, and is completely abolished by methylation of this agent[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:EGFR-driven A431 cancer cell line
-
Concentration:0.078, 0.156, 0.313, 0.625, 1.25, 2.5, 5, 10 μM
-
Incubation Time:72 h
-
Result:Exhibited no significant inhibition of A431 cell viability at concentrations up to 10 μM.
-
Cell Line:BT-474 and NCI-N87 cancer cell lines
-
Concentration:10, 50, 100, 250, 500, 1000 nM (concentration-dependent degradation)
200 nM (time-course degradation)
500 nM (24 h incubation) -
Incubation Time:1, 3, 6, 12, 24 h (time-course degradation)
24 h (concentration-dependent and fixed-concentration incubation) -
Result:Induced concentration-dependent HER2 degradation with a DC50 of 69 nM and Dmax of 96% in BT-474 cells.
Induced concentration-dependent HER2 degradation with a DC50 of 55 nM and Dmax of 94% in NCI-N87 cells.
Caused significant HER2 degradation within 3 h of treatment with 200 nM.
-
Cell Line:BT-474 and NCI-N87 cancer cell lines
-
Concentration:10, 100, 250, 1000 nM (24 h incubation)
200 nM (24 h incubation with wash-out) -
Incubation Time:24 h (incubation)
0, 3, 6, 12, 24 h (wash-out culture) -
Result:Induced concentration-dependent reduction in HER2 autophosphorylation, and phosphorylation of AKT and ERK1/2, without altering total AKT or ERK1/2 protein levels in both cell lines.
Sustained HER2 degradation and inhibition of AKT/ERK phosphorylation for over 12 h after 24 h treatment with 200 nM followed by wash-out.
Showed no significant HER2 rebound until 24 h after wash-out.
-
Cell Line:BT-474 cancer cell lines
-
Concentration:200 nM (co-treated with inhibitors); 1 μM methylated CH7C4
-
Incubation Time:2 h (pre-treatment); 24 h (co-treatment and methylated CH7C4 incubation)
-
Result:Had HER2 degradation completely blocked by pre-treatment with 1 μM MLN4924 (HY-70062), 1 μM MG132 (HY-13259), 1 μM cereblon ligand, or 1 μM human epidermal growth factor receptor 2 inhibitor.
Parmacokinetics
| Species | Dose | Route | AUCinf | T1/2 | CL | Vss | AUCall |
|---|---|---|---|---|---|---|---|
| Rat | 2 mg/kg | i.p. | 3214 ng·h/mL | 5.31 h | 12.1 mL/min/kg | 1048 mL/kg | 3089 ng·h/mL |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (6‑week‑old female) were firstly subcutaneously inoculated with 1 × 107 BT‑474 cells.
Tumor fragments (20‑100 mg) from primary tumors were re‑implanted into new mice. -
Dosage:5 mg/kg; 10 mg/kg
-
Administration:i.v.; daily; 21 days
-
Result:Achieved a tumor growth inhibition (TGI) of 47%.
Achieved a tumor growth inhibition (TGI) of 73%.
Confirmed significant HER2 degradation in vivo via western blot analysis of tumor tissues.
Caused no significant side effects or weight loss during treatment.
Chemical Information
-
CAS No. 2897640-93-4
-
Appearance Solid
-
Molecular Weight 910.03
-
Formula C49H55N11O7
-
Color Light yellow to yellow
-
SMILES
O=C1C2=CC=C(NCCCCCCCN3CCN(CCCOC4=CC5=NC=NC(NC6=CC=C(C(C)=C6)OC7=CC8=NC=NN8C=C7)=C5C=C4OC)CC3)C=C2C(N1C9C(NC(CC9)=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)